Ongoing improvements in specialty coating platforms are expanding the number of active compounds are can be formulated as drug-device combination products. “We expect the clinical results from the current generation of coated device designs to yield valuable insight that will accelerate technology improvements, resulting in coating formulations that can be further tailored to specific therapeutic targets,” explains George Perros, Greystone Managing Director.
The potential impact is far-reaching. The number of conditions requiring interventional therapeutics that can potentially benefit from drug eluting combination devices is significant. “The early success of drug eluting devices such as the CypherÔ stent is resulting in increased interest in coated device combination delivery systems for a host of conditions, based on a growing list of substrates,” adds Perros.
These survey findings are contained in a new and comprehensive report: Drug Delivery Coatings: Devices, Therapies and Emerging Opportunities. The report contains a comprehensive assessment of drug eluting coating technology, and provides an assessment of current and probably future coated drug-device combination products, profiles of market participants, industry data and forecasts, and detailed analysis of regulatory and market factors. Organized and written to be of maximum value to pharmaceutical professionals, device developers, drug delivery market participants, and coating technology providers, the report provides a detailed analysis of the growing potential for coating-enabled drug eluting devices in interventional therapeutics.
More information is available at www.greystoneassociates.org .
Greystone Associates is a medical and healthcare technology consulting firm providing services in strategic planning, venture development, product commercialization, and technology and market assessment.
www.greystoneassociates.org Source: Greystone Associates
For more information:
Last updated on: 27/08/2010